undamentalytics Newsletter
Sign in

Vivosim Labs, Inc. balance sheet

At the end of fiscal 2026, Vivosim Labs, Inc. had total assets of $7.4m, total liabilities of $8.5m and shareholders' equity of −$1.1m. It held $5.0m in cash against $0 of debt: net cash of $5.0m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20102012Dec 20112013Dec 20122014Mar 20142015Mar 20152016Mar 20162017Mar 20172018Mar 20182019Mar 20192020Mar 20202021Mar 20212022Mar 20222023Mar 20232024Mar 20242025Mar 20252026Mar 2026LTMJun 2026
Cash and equivalents———4850626344362737291531152
Receivables————0011100000000
Inventory—000001100——000——
Total current assets—1164951646547392838301741273
Total assets—1175053686950412840332061574
Accounts payable—1001110110001211
Deferred revenue (current)—0—0011110———————
Total current liabilities—22225465421142432
Total debt01000000000000000
Total liabilities—32225575421353486
Shareholders' equity−2−2−548496262453627393015410−1−2
Net debt (negative = net cash)———−48−50−62−63−44−36−27−37−29−15−3−11−5−2
Shares outstanding—————————————2m—3m3m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: IBIO vs VIVSLSTA vs VIVSAIM vs VIVS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Vivosim Labs, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Vivosim Labs, Inc.